Wupper\u00adtal \u2014 The globally active Chinese group WuXi Biolo\u00adgics has comple\u00adted the acqui\u00adsi\u00adtion of a plant for biolo\u00adgi\u00adcal subs\u00adtances from Bayer AG in Wupper\u00adtal. The closing took place in Colo\u00adgne on April 30, 2021. A team led by Dirk W. Kolven\u00adbach, Part\u00adner at the D\u00fcssel\u00addorf office, and Michael Pauli from the Colo\u00adgne office of Heuking K\u00fchn L\u00fcer Wojtek provi\u00added legal advice to the Chinese group on the purchase. The tran\u00adsac\u00adtion volume, inclu\u00adding the lease, is around \u20ac150 million. The tran\u00adsac\u00adtion is expec\u00adted to close in the first half of 2021 and is subject to regu\u00adla\u00adtory review.<\/p>\n
The new faci\u00adlity in Wupper\u00adtal is one of the largest vaccine produc\u00adtion sites in Germany and will be used to manu\u00adfac\u00adture highly sought-after subs\u00adtances for COVID-19 vacci\u00adnes and other biolo\u00adgics. WuXi Biolo\u00adgics plans addi\u00adtio\u00adnal invest\u00adments in process equip\u00adment at the Wupper\u00adtal site. \u201cWe are very proud to have provi\u00added legal support for the purchase of this major vaccine produc\u00adtion faci\u00adlity,\u201d said attor\u00adney Dirk W. Kolven\u00adbach. \u201cThrough this tran\u00adsac\u00adtion, we can also make an important contri\u00adbu\u00adtion on an advo\u00adcacy level for vaccine manu\u00adfac\u00adtu\u00adring, inclu\u00adding COVID-19 vacci\u00adnes, in Germany.\u201d<\/p>\n
With the conclu\u00adsion of the agree\u00adment, Bayer and WuXi Biolo\u00adgics have at the same time ente\u00adred into a long-term sublease and a service agree\u00adment. Bayer will provide various services to WuXi Biolo\u00adgics during the start-up of the plant, contri\u00adbu\u00adting its own resour\u00adces. The signing alre\u00adady took place on Decem\u00adber 21, 2020. The tran\u00adsac\u00adtion volume, inclu\u00adding the lease, is over 150 million euros.<\/p>\n
WuXi Biolo\u00adgics is listed on the Hong Kong Stock Exch\u00adange and is a leading global open access biolo\u00adgics tech\u00adno\u00adlogy plat\u00adform. The company provi\u00addes end-to-end solu\u00adti\u00adons to help compa\u00adnies disco\u00adver, deve\u00adlop and manu\u00adfac\u00adture biolo\u00adgics from concept to commer\u00adcial produc\u00adtion. For Kolven\u00adbach\u2019s team, this is not the first tran\u00adsac\u00adtion for WuXi. Heuking had alre\u00adady advi\u00adsed WuXi Biolo\u00adgics on the acqui\u00adsi\u00adtion of a drug formu\u00adla\u00adtion plant from Bayer in 2020.<\/p>\n
Advi\u00adsor to WuXi Biolo\u00adgics: Heuking K\u00fchn L\u00fcer Wojtek<\/strong> Wupper\u00adtal \u2014 The globally active Chinese group WuXi Biolo\u00adgics has comple\u00adted the acqui\u00adsi\u00adtion of a plant for biolo\u00adgi\u00adcal subs\u00adtances from Bayer AG in Wupper\u00adtal. The closing took place in Colo\u00adgne on April 30, 2021. A team led by Dirk W. Kolven\u00adbach, Part\u00adner at the D\u00fcssel\u00addorf office, and Michael Pauli from the Colo\u00adgne office of Heuking [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37329,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368,1371,1372,1377],"tags":[],"class_list":["post-43498","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-deals-en","category-consultant","category-corporate-finance-ma","news-category-deals-news-en"],"yoast_head":"\n
\nDirk W. Kolven\u00adbach (Corpo\u00adrate Law\/ Project Coor\u00addi\u00adna\u00adtion), D\u00fcsseldorf
\nMichael Pauli, LL.M. (Corpo\u00adrate Law\/Project Coor\u00addi\u00adna\u00adtion), Cologne
\nMathis Dick, LL.M. (Real Estate), D\u00fcsseldorf
\nMichael Below, (Public Law), D\u00fcsseldorf
\nDr. Bodo Dehne (invest\u00adment control), D\u00fcsseldorf
\nWolf\u00adram Meven (Tax Law), D\u00fcsseldorf
\nDr. Rainer Velte (Anti\u00adtrust Law), D\u00fcsseldorf
\nFabian Gerst\u00adner, LL.M., Munich, Bettina Nehe\u00adi\u00adder (both Cons\u00adtruc\u00adtion Law), Munich
\nDr. Tobias Plath, LL.M. (Insu\u00adrance Law), Tors\u00adten Gro\u00df, LL.M. (Labor Law), Sarah Radon, LL.M. (Commer\u00adcial), all D\u00fcsseldorf<\/p>\n","protected":false},"excerpt":{"rendered":"